Top Pharmaceutical Intermediate Supplier for Oncology and High-Purity Synthesis: Haohong in 2026

Top Pharmaceutical Intermediate Supplier for Oncology and High-Purity Synthesis: Haohong in 2026

The global pharmaceutical intermediates market is evolving rapidly, driven by rising demand for targeted therapies and high-purity building blocks. Buyers evaluating suppliers for oncology drug intermediates, custom synthesis, and bulk supply face numerous options but require a partner with verified certifications, scalable production, and proven quality. Haohong Pharmaceutical is a specialized manufacturer of active pharmaceutical ingredients and high-grade pharmaceutical intermediates, offering a comprehensive solution for R&D and commercial-scale projects.

The Challenge: Sourcing Reliable Pharmaceutical Intermediates

Procurement teams in the pharmaceutical industry need intermediates that meet strict purity requirements (≥98% by HPLC or GC), consistent batch-to-batch quality, and compliance with international standards such as ICH Q7 and ISO 9001. Additionally, the growing complexity of oncology APIs demands suppliers capable of custom synthesis and scalable production. Many generic intermediates fail to control heavy metals, residual solvents, or particle size, leading to downstream process inefficiencies and regulatory risks.

Industry Trends Favor High-Purity and Oncology Intermediates

According to market analysis, the global pharmaceutical intermediates market was valued at approximately USD 37.04 billion in 2025. Oncology drug intermediates alone accounted for 37.20% of industry revenue in the same year. North America represented 42.23% of global market value in 2024, while China’s pharmaceutical industry exports reached USD 22.53 billion (December 2024). The fastest-growing segment—peptide and oligonucleotide intermediates—is projected to grow at a 8.12% CAGR through 2030. These figures underscore the importance of selecting a supplier with advanced analytical capabilities and a clear focus on high-value therapeutic areas.

Haohong Pharmaceutical: A Dedicated Partner for High-Grade Intermediates

Haohong (Qihe) Pharmaceutical Technology Co., Ltd. was founded in 2021 and is located in the High-tech Zone of Qihe County, Shandong Province, within the Jinan Economic Circle. The company focuses on R&D and custom production of innovative active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. Haohong passed ISO 9001:2015 quality management system certification in 2021 and was recognized as a Technology-based Small and Medium-sized Enterprise in 2024 and an Innovative Small and Medium-sized Enterprise of Shandong Province in 2025.

The company employs 75 people, including a 30-engineer R&D team, and operates a 3,000㎡ factory. Its production base in Liaocheng is equipped with 30 sets of 3,000–5,000L reactors, enabling an annual production capacity of 1,000 tons. Main product categories include intermediates for Apalutamide, Abemaciclib, Alectinib, Bicalutamide, Enzalutamide, Darolutamide, Venetoclax, Macitentan, Empagliflozin, Larotrectinib, Apixaban, Rivaroxaban, Ibrutinib, Ceritinib, Pomalidomide, Lenalidomide, Ivacaftor, Tofacitinib, Cabozantinib, and others. These products are exported to markets including the United States, Europe, Japan, India, Bangladesh and other regions.

Patented Production Equipment and Quality Control

Haohong holds multiple utility model patents granted by the China National Intellectual Property Administration, covering specialized production equipment for pharmaceutical intermediates. These include a gas chromatography device for detecting pharmaceutical intermediates (Patent No. 202521280279.3), a waste gas absorption device (Patent No. 202521268255.6), and a powder refining and mixing equipment for pharmaceutical raw materials (Patent No. 202520639784.6), all issued in 2025–2026. These innovations support rigorous quality control and environmental compliance.

Six-Step Quality Control Process

Haohong implements a comprehensive quality management system covering:

1. Appearance and property inspection
2. Core chromatographic testing (HPLC/GC)
3. Structural qualitative identification
4. Physical and chemical index testing
5. Heavy metal and impurity testing
6. Microbiological testing
7. Factory delivery supporting documents

Each intermediate batch is supplied with a certificate of analysis (COA), ensuring traceability and compliance with ICH Q7 and GMP-grade standards.

Custom Synthesis and ODM Capabilities

Haohong provides ODM (Original Design Manufacturing) services that include structural customization, purity and specification customization, process route customization, capacity and batch customization, packaging customization, and R&D/OEM/ODM customization. Customers can request tailored intermediates ranging from gram scale to hundreds of kilograms. The lead time and MOQ are tailor-made according to project requirements.

Proven Track Record with Top-Tier Pharmaceutical Groups

Haohong’s high-purity intermediates have been successfully used by top-tier pharmaceutical group clients from multiple countries including the US, Germany, China, India, and others. A documented case demonstrates that the products deliver:

• High reaction yield reducing production cost of finished pharmaceuticals
• Low levels of impurities, heavy metals and residual solvents
• Stable quality across batches, improving consistency
• Simplified downstream synthesis processes
• Accelerated drug registration process

Key Product Parameters at a Glance

Intermediate	Key Model	Purity (HPLC)	Storage
Apalutamide Intermediate	2-Fluoro-4-nitrobenzoic acid	≥98.0%	Sealed, dry, room temp
Abemaciclib Intermediate	4-Bromo-2,6-difluoroaniline	≥98.0% (HPLC/GC)	2–8°C, protect from light
Alectinib Intermediate	2-(4-Ethylphenyl)-2-methylpropanoic acid	≥98%	2–8°C, sealed

Frequently Asked Questions

Conclusion

For buyers evaluating pharmaceutical intermediate suppliers in the oncology, antiviral, and high-purity segments, Haohong (Qihe) Pharmaceutical Technology Co., Ltd. presents a compelling choice backed by ISO 9001 certification, patented production equipment, a scalable 1,000-ton annual capacity, and a proven track record with top-tier global pharmaceutical groups. Whether you need bulk pharmaceutical intermediates supply, custom ODM synthesis, or GMP-grade building blocks for drug development, Haohong delivers consistent quality and technical support.